文献速递慢性肾脏病肾血管病与高血压血液净化与透析

SGLT2抑制剂与GLP-1受体激动剂在不同肾衰竭风险下的肾脏与心血管结局比较

Comparative Effectiveness of SGLT2 Inhibitor and GLP-1 Receptor Agonist on Kidney and Cardiovascular Outcomes by Kidney Failure Risk.
PubMed 文献 · J Am Soc Nephrol · 2026-01-13

该研究纳入160,428例2型糖尿病退伍军人,比较SGLT2抑制剂、非艾塞那肽类GLP-1受体激动剂与甘精胰岛素的新使用者。经逆概率加权后分析显示,SGLT2抑制剂与GLP-1受体激动剂相比全因死亡风险相似、肾衰竭风险有降低趋势但心血管事件风险略高;肾衰竭风险方程评分可修饰两种药物的比较效果。

要点

  • 低肾衰竭风险时SGLT2抑制剂肾脏保护更优,GLP-1受体激动剂心血管保护更优。
  • 中风险(KFRE 2%-6%)时GLP-1受体激动剂对肾脏和心血管复合结局更有利。
  • 高风险(KFRE≥6%)时SGLT2抑制剂对肾脏和心血管复合结局更有利。

核心结论

  • 整体队列中,与GLP-1受体激动剂相比,SGLT2抑制剂死亡风险相当、肾衰竭风险有降低趋势但心血管事件风险略高。
  • 肾衰竭风险方程评分可修饰两种药物的比较效果:中风险时GLP-1受体激动剂更优,高风险时SGLT2抑制剂更优。

研究设计与样本

  • 共纳入160,428例退伍军人,其中SGLT2抑制剂、GLP-1受体激动剂和甘精胰岛素新使用者分别占53%、14%和34%。
  • 采用逆概率治疗加权平衡基线特征,随访至2023年3月31日,并检验肾衰竭风险方程评分对药物比较效果的影响修饰。

主要发现

  • 与GLP-1受体激动剂新使用者相比,SGLT2抑制剂新使用者全因死亡风险相似,肾衰竭风险有降低趋势(HR 0.89;95%CI 0.74-1.06)。
  • 与GLP-1受体激动剂新使用者相比,SGLT2抑制剂新使用者主要不良心血管事件风险更高(HR 1.14;95%CI 1.09-1.20),心血管-肾脏-代谢复合结局风险也更高(HR 1.13;95%CI 1.08-1.19)。
  • 除全因死亡外,SGLT2抑制剂与GLP-1受体激动剂的效应在中风险(2%-6%)与高风险(≥6%)KFRE亚组间差异显著。
  • 中风险KFRE者中GLP-1受体激动剂对肾衰竭、主要不良心血管事件和心血管-肾脏-代谢复合结局似乎更保护,高风险KFRE者中SGLT2抑制剂似乎更保护。

临床怎么用

  • 肾衰竭风险方程评分可能作为临床工具,用于指导2型糖尿病患者的降糖药物选择。
  • 中风险KFRE患者可优先考虑GLP-1受体激动剂以获取更优的肾脏和心血管保护。
  • 高风险KFRE患者可优先考虑SGLT2抑制剂以获取更优的肾脏和心血管保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: In veterans with type 2 diabetes and low kidney failure risk, sodium-glucose cotransporter 2 inhibitors (SGLT2is) were more kidney protective while glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were more cardioprotective. For cardiovascular-kidney-metabolic outcomes, GLP-1 RAs were more protective at moderate kidney failure risk and SGLT2is were more protective at high kidney failure risk. The kidney failure risk equation might be a clinically useful tool to guide therapy in type 2 diabetes. BACKGROUND: Head-to-head comparisons of non-exendin glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) on kidney failure or cardiovascular-kidney-metabolic (CKM) composite end points are lacking. Whether kidney failure risk modifies the comparative effectiveness of GLP-1 RA versus SGLT2i is clinically relevant. METHODS: We defined a national veterans cohort with type 2 diabetes who initiated an SGLT2i, non-exendin GLP-1 RA, or insulin glargine between January 1, 2018, and December 31, 2021. After applying inverse probability of treatment weighting to balance baseline characteristics, outcomes were compared across new-user groups through March 31, 2023. Outcomes included kidney failure (stage 5 CKD or long-term KRT), major adverse cardiovascular events (MACEs: heart failure, myocardial infarction, or stroke), CKM composite (kidney failure or MACE), all-cause death, and composites of outcomes with death. We tested for effect modification by the kidney failure risk equation (KFRE) score on comparative pairwise drug effectiveness. RESULTS: Out of 160,428 veterans, 53%, 14%, and 34% were new users of SGLT2i, GLP-1 RA, and insulin glargine, respectively. Relative to GLP-1 RA new-users, SGLT2i new-users had similar mortality risk, a trend toward lower kidney failure risk (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.74 to 1.06), but higher risk of MACE (HR, 1.14; 95% CI, 1.09 to 1.20) and CKM composite (HR, 1.13; 95% CI, 1.08 to 1.19). The effect of SGLT2i versus GLP-1 RA differed significantly between moderate-risk (2%-6%) and high-risk (≥6%) KFRE subgroups for all outcomes except all-cause death. In those with moderate-risk KFRE, GLP-1 RA seemed more protective for kidney failure, MACE, and CKM composite, while SGLT2i appeared more protective in those with high-risk KFRE. CONCLUSIONS: Compared with GLP-1 RA, SGLT2i had comparable risks of mortality, perhaps a lower risk of kidney failure, but modestly higher risk of cardiovascular events in the entire cohort. However, GLP-1 RA were more beneficial in those with moderate kidney failure risk and SGLT2i more beneficial in those with high kidney failure risk. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3//www.asn-online.org/media/podcast/JASN/2026_07_29_KTS_July2026.mp3.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Hartsell SE, Wei G, Singh R, et al. Comparative Effectiveness of SGLT2 Inhibitor and GLP-1 Receptor Agonist on Kidney and Cardiovascular Outcomes by Kidney Failure Risk. J Am Soc Nephrol. 2026. PMID: 41563358. doi:10.1681/ASN.0000001016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。